An interventional study of Tobacco counseling resources in Tobacco Use and Tobacco Use Cessation, sponsored by University of Pennsylvania. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by University of Pennsylvania · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 313 studies in Tobacco Use with a site in United States — 54 open to participants now, 65 under way, 1 of them phase 3. Tobacco Use · United States.
Among the 313 studies in Tobacco Use with a site in United States, this one is the 5th largest by planned enrollment of the 288 interventional ones that give a count, is one of 14 that started in 2026, is one of 233 with no phase, reaches primary completion later than 21 of the 64 other live ones, and was the 306th registered.
423 studies on the registry are indexed under Tobacco Use; 85 are open to participants now.
Browse Tobacco Use studies →54 of the 313 studies in Tobacco Use with a site in United States are open now. Recruiting first, the newest first:
RAI Services Company · Sites in United States
Ages 21–65 · Healthy volunteers
RAI Services Company · Sites in United States
Ages 21–65 · Healthy volunteers
RAI Services Company · Sites in United States
Ages 21–65 · Healthy volunteers
University of Pittsburgh · Sites in United States
Ages 18+ · Women only
RAI Services Company · Sites in United States
Ages 21–65 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 51 Tobacco Use studies recruiting now, 28 (55%) set no upper age limit and 19 (37%) stop at 75 or younger; 2 take children under 18; 28 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
313 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 22 · Phase 3 10 · Phase 4 9
First in 1992; this study’s year is marked. 14 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 4,800 is above the median of 131 across 354 interventional studies indexed under Tobacco Use.
Median enrollment 120 across the 288 interventional studies, 174 across the 24 observational. Of the 232 that completed or were terminated, 82 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
68 of 313 have an industry lead sponsor. The 10 most frequent:
University of Pennsylvania is the lead sponsor of 1,668 studies on the registry; 229 are open to participants now.
Of its 160 completed or terminated interventional studies of FDA-regulated products, 110 (69%) have results posted.
University of Pennsylvania has 5 studies filed under Tobacco Use — fewer than ten, so there is no comparison to draw.
33 of the studies in Tobacco Use with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05707871Wake Forest University Health SciencesCardiovascular Effects of Very Low Nicotine Content Cigarettes | 2026-12 |
| NCT07710820RAI Services CompanyA Multi-Site Study to Assess the Effect of Availability of a Heated Tobacco Product on Smoking Abstinence Among Current Primary Cigarette Smokers | 2026-12 |
| NCT05445804Johns Hopkins UniversityOral Cannabidiol for Tobacco Cessation | 2026-12-01 |
| NCT07598136RAI Services CompanyA Study to Determine the Effects of ENDS Flavor Availability on Abstinence Within Smokers | 2026-12-17 |
| NCT04297592Mayo ClinicAntibiotic Prophylaxis in High-Risk Arthroplasty Patients | 2027-01 |
Add all 33 to your calendar (.ics) → With an account.
Among the 313 studies in Tobacco Use with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study focuses on improving how primary care teams identify patients who smoke and offer access to nicotine replacement therapy, or NRT. NRT includes medications such as nicotine patches, gum, or lozenges that can reduce cravings and support people who are interested in cutting back or quitting smoking. Although NRT is an evidence-based treatment option, it is not always discussed or prescribed during routine primary care visits. To better understand how NRT can be offered in primary care, the project will test a workflow at Penn Family Care that identifies patients who currently smoke and provides information about available tobacco treatment options. Edward Cooper Internal Medicine will serve as a comparison site. Patients who smoke and/or are prescribed NRT will also receive a 30-day follow-up survey to learn whether they received, picked up, or used NRT; whether it was useful; and what barriers they experienced.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Interested participants will receive a text with tobacco counseling resources
Behavioral: Tobacco counseling resources
No text with tobacco counseling resources
Participants who are in the intervention arm will receive tobacco counseling resources via the Way to Health platform. Way to Health will send text message links to tobacco cessation counseling resources (PA Quitline and/or SmokeFreeTXT).
Proportion of Active Smokers with a Signed NRT Prescription
The primary outcome will be proportion of patients with a signed NRT prescription (signed between 3 days prior to scheduled visit and 30 days after completed visit) among those documented as active smokers in the EHR as of this visit who did not have an NRT prescription in the 34 to 4 days prior. A sensitivity analysis will include additional patients identified as smokers through pre-visit surveys.
Time frame: From 3 days before scheduled visit and 30 days after completed visit.
Sensitivity of EHR Active Smoker Designation
Sensitivity of EHR active smoker designation using tobacco questionnaire response as benchmark (Treatment-site Secondary Outcome Measure 1)
Time frame: At completion of pre-visit tobacco questionnaire (baseline)
Specificity of EHR Active Smoker Designation
Specificity of EHR active smoker designation using tobacco questionnaire response as benchmark (Treatment-site Secondary Outcome Measure 2)
Time frame: At completion of pre-visit tobacco questionnaire (baseline)
Accuracy of EHR Active Smoker Designation
Accuracy of EHR active smoker designation using tobacco questionnaire response as benchmark (Treatment-site Secondary Outcome Measure 3)
Time frame: At completion of pre-visit tobacco questionnaire (baseline)
Proportion of Tobacco Questionnaire-Identified Smokers Selecting Each Benefit of Quitting
Proportion of tobacco questionnaire-identified smokers who select each benefit of quitting (Treatment-site Secondary Outcome Measure 4)
Time frame: At completion of the pre-visit tobacco questionnaire (baseline)
Proportion of Tobacco Questionnaire-Identified Smokers Selecting Each of the Three Treatments
Proportion who select each of the three treatments (Treatment-site Secondary Outcome Measure 5)
Time frame: At completion of the pre-visit tobacco questionnaire (baseline)
Proportion of Participants Selecting NRT Whose Clinician Signs the Pended Order
Proportion selecting NRT whose clinician signs the pended order (Treatment-site Secondary Outcome Measure 6)
Time frame: From completion of the pre-visit tobacco questionnaire through 30-days after the completed visit
Proportion of Participants With Any NRT Prescription Recorded in the EHR
Any NRT prescription in the EHR during the study period (Both-sites Secondary Outcome Measure 7)
Time frame: From study start for first participant to 6 months later
Proportion of Participants Reporting NRT Use at 30-Day Follow-Up
30-day self-reported NRT use (Both-sites Secondary Outcome Measure 8)
Time frame: 30 days after completed visit, at time of follow-up survey completion
Proportion of Participants Reporting Engagement With Tobacco Cessation Counseling Resources at 30-Day Follow-Up
30-day self-reported engagement with tobacco cessation counseling resources (Both-sites Secondary Outcome Measure 9)
Time frame: 30 days after completed visit, at time of follow-up survey completion
Proportion of Participants Reporting Each Smoking Status at 30-Day Follow-Up
30-day self-reported smoking status (Both-sites Secondary Outcome Measure 10)
Time frame: 30 days after completed visit, at time of follow-up survey completion
Proportion of Participants Reporting Changes in Smoking Behavior at 30-Day Follow-Up
30-day self-reported changes in smoking behavior (Both-sites Secondary Outcome Measure 11)
Time frame: 30 days after completed visit, at time of follow-up survey completion
Proportion of Participants With a New or Refill NRT Prescription Recorded in the EHR
New/refill NRT prescription in EHR 30-60 days after completed visit (Both-sites Secondary Outcome Measure 12)
Time frame: 30 to 60 days after the completed visit
Started Sep 2026 (actual). Primary completion is estimated for Mar 2027, 5 months after the start.
Of 167 non-industry interventional studies with no phase under Tobacco Use, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 41. This study's planned 5 months is below that.
Counting every sponsor, half of 224 studies reached it within 16 months; a quarter within 5 and three quarters within 33.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.